1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Diabetes – Pipeline Review, H1 2013

Diabetes – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 359 pages

Diabetes – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Diabetes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. Diabetes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Diabetes.
- A review of the Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetes pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Diabetes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetes pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Diabetes - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
Introduction 6
Diabetes Overview 7
Therapeutics Development 8
Diabetes Therapeutics under Development by Companies 10
Diabetes Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 20
Mid Clinical Stage Products 21
Early Clinical Stage Products 22
Discovery and Pre-Clinical Stage Products 23
Diabetes Therapeutics - Products under Development by Companies 24
Diabetes Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Diabetes Therapeutics Development 36
Diabetes - Therapeutics Assessment 120
Drug Profiles 127
Diabetes Therapeutics - Drug Profile Updates 308
Diabetes Therapeutics - Discontinued Products 324
Diabetes Therapeutics - Dormant Products 327
Diabetes - Product Development Milestones 333
Appendix 340

List of Tables

Number of Products Under Development for Diabetes, H1 2013 26
Products under Development for Diabetes - Comparative Analysis, H1 2013 27
Number of Products under Development by Companies, H1 2013 29
Number of Products under Development by Companies, H1 2013 (Contd..1) 30
Number of Products under Development by Companies, H1 2013 (Contd..2) 31
Number of Products under Development by Companies, H1 2013 (Contd..3) 32
Number of Products under Development by Companies, H1 2013 (Contd..4) 33
Number of Products under Development by Companies, H1 2013 (Contd..5) 34
Number of Products under Development by Companies, H1 2013 (Contd..6) 35
Number of Products under Development by Companies, H1 2013 (Contd..7) 36
Number of Products under Investigation by Universities/Institutes, H1 2013 37
Comparative Analysis by Late Stage Development, H1 2013 38
Comparative Analysis by Mid Clinical Stage Development, H1 2013 39
Comparative Analysis by Early Clinical Stage Development, H1 2013 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 41
Products under Development by Companies, H1 2013 42
Products under Development by Companies, H1 2013 (Contd..1) 43
Products under Development by Companies, H1 2013 (Contd..2) 44
Products under Development by Companies, H1 2013 (Contd..3) 45
Products under Development by Companies, H1 2013 (Contd..4) 46
Products under Development by Companies, H1 2013 (Contd..5) 47
Products under Development by Companies, H1 2013 (Contd..6) 48
Products under Development by Companies, H1 2013 (Contd..7) 49
Products under Development by Companies, H1 2013 (Contd..8) 50
Products under Development by Companies, H1 2013 (Contd..9) 51
Products under Development by Companies, H1 2013 (Contd..10) 52
Products under Investigation by Universities/Institutes, H1 2013 53
Bristol-Myers Squibb Company, H1 2013 54
Baxter International Inc., H1 2013 55
Sanofi-Aventis, H1 2013 56
Eli Lilly and Company, H1 2013 57
Athersys, Inc., H1 2013 58
Daiichi Sankyo Company, Ltd, H1 2013 59
Cytokine PharmaSciences, Inc., H1 2013 60
Meytav Technological Incubator, H1 2013 61
Ipsen S.A., H1 2013 62
Astellas Pharma Inc., H1 2013 63
Biocon Limited, H1 2013 64
Dong-A Pharmaceutical Co., Ltd., H1 2013 65
Pfizer Inc., H1 2013 66
Rigel Pharmaceuticals, Inc., H1 2013 67
Zydus Cadila Healthcare Limited, H1 2013 68
Biodel Inc., H1 2013 69
Zosano Pharma, Inc., H1 2013 70
Access Pharmaceuticals, Inc., H1 2013 71
GENTIUM S.p.A., H1 2013 72
GW Pharmaceuticals plc, H1 2013 73
Insmed Incorporated, H1 2013 74
Genfit, H1 2013 75
Ligand Pharmaceuticals Incorporated, H1 2013 76
Lupin Limited, H1 2013 77
NexMed, Inc., H1 2013 78
Opexa Therapeutics, Inc., H1 2013 79
Oramed Pharmaceuticals, Inc., H1 2013 80
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 81
ConjuChem Biotechnologies Inc., H1 2013 82
SANWA KAGAKU KENKYUSHO CO.,LTD., H1 2013 83
Yuhan Corporation, H1 2013 84
Array BioPharma Inc., H1 2013 85
Torrent Pharmaceuticals Limited, H1 2013 86
Choongwae Pharma Corp, H1 2013 87
Hanall Pharmaceutical Co., Ltd., H1 2013 88
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 89
HYUNDAI PHARM. CO., LTD., H1 2013 90
Suven Life Sciences Ltd., H1 2013 91
Galapagos NV, H1 2013 92
Panacea Biotec Limited, H1 2013 93
Summit Corporation plc, H1 2013 94
Proximagen Neuroscience plc., H1 2013 95
Transgene Biotek Ltd, H1 2013 96
Hybrigenics S.A., H1 2013 97
Angelini Group, H1 2013 98
Betagenon AB, H1 2013 99
Biotecnol SA, H1 2013 100
Jenrin Discovery, Inc., H1 2013 101
Phosphagenics Limited, H1 2013 102
Domain Therapeutics, H1 2013 103
Metabolex, Inc, H1 2013 104
Xenon Pharmaceuticals Inc., H1 2013 105
Spherix Incorporated, H1 2013 106
Ambrx, Inc., H1 2013 107
Five Prime Therapeutics, Inc., H1 2013 108
Diabetology Limited, H1 2013 109
Conatus Pharmaceuticals Inc., H1 2013 110
MSM Protein Technologies, Inc., H1 2013 111
Zealand Pharma A/S, H1 2013 112
Indus Biotech Private Limited, H1 2013 113
Vantia Therapeutics, H1 2013 114
Omeros Corporation, H1 2013 115
Aegis Therapeutics, LLC, H1 2013 116
Peptron, Inc., H1 2013 117
Immunocore Limited., H1 2013 118
Molecular Design International, Inc., H1 2013 119
Kalypsys, Inc., H1 2013 120
PepTcell Limited, H1 2013 121
Tris Pharma, Inc., H1 2013 122
Vitae Pharmaceuticals, Inc., H1 2013 123
Limerick BioPharma, Inc., H1 2013 124
Glucox Biotech, H1 2013 125
Diakron Pharmaceuticals, Inc., H1 2013 126
Adocia, H1 2013 127
Amplimmune, Inc., H1 2013 128
DiscoveryBiomed, Inc., H1 2013 129
Signum Biosciences, Inc., H1 2013 130
Envoy Therapeutics, Inc., H1 2013 131
Nuvilex, Inc., H1 2013 132
Revivicor, Inc., H1 2013 133
PharmaIN Corporation, H1 2013 134
AUS Bio Limited, H1 2013 135
Advancell, H1 2013 136
Rhythm Pharmaceuticals, H1 2013 137
Assessment by Monotherapy Products, H1 2013 138
Assessment by Combination Products, H1 2013 139
Assessment by Stage and Route of Administration, H1 2013 141
Assessment by Stage and Molecule Type, H1 2013 144
Diabetes Therapeutics - Drug Profile Updates 326
Diabetes Therapeutics - Discontinued Products 342
Diabetes Therapeutics - Discontinued Products (Contd..1) 343
Diabetes Therapeutics - Discontinued Products (Contd..2) 344
Diabetes Therapeutics - Dormant Products 345
Diabetes Therapeutics - Dormant Products (Contd..1) 346
Diabetes Therapeutics - Dormant Products (Contd..2) 347
Diabetes Therapeutics - Dormant Products (Contd..3) 348
Diabetes Therapeutics - Dormant Products (Contd..4) 349
Diabetes Therapeutics - Dormant Products (Contd..5) 350

List of Figures

Number of Products under Development for Diabetes, H1 2013 26
Products under Development for Diabetes - Comparative Analysis, H1 2013 27
Products under Development by Companies, H1 2013 28
Products under Investigation by Universities/Institutes, H1 2013 37
Late Stage Products, H1 2013 38
Mid Clinical Stage Products, H1 2013 39
Early Clinical Stage Products, H1 2013 40
Discovery and Pre-Clinical Stage Products, H1 2013 41
Assessment by Monotherapy Products, H1 2013 138
Assessment by Combination Products, H1 2013 139
Assessment by Route of Administration, H1 2013 140
Assessment by Stage and Route of Administration, H1 2013 141
Assessment by Molecule Type, H1 2013 142
Assessment by Stage and Molecule Type, H1 2013 143

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glucose Dependent Insulinotropic Receptor (G Protein ...

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.